When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease “in their genes”? It’s an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests that DNA sequence alone tells only part of the story, and increasingly, scientists believe it may be the smaller part. The rest of the story is largely written in epigenetics, a field of biology that examines how genes are switched on or off, turned up or down, without any change to the underlying DNA code itself.
Cardio Diagnostics Holdings (NASDAQ: CDIO), a medical technology company built around epigenetics-based cardiovascular testing, has positioned this science at the center of its diagnostic platform. Looking at an individual person’s epigenetics can provide invaluable insight into the impact of their lifestyle, behavior, and environment. Epigenetics does more than pinpoint a problem, says CEO; it also provides some level of solution.
Understanding the basic concept of epigenetics is key. Think of DNA as a massive instruction manual containing every gene a person could ever use. That manual does not change much over a lifetime. What does change is which pages get read, how often and how loudly. Epigenetics is essentially the mechanism that controls gene expression. For example, two people might have the same genetic predisposition for heart disease, but one might have epigenetic marks that suppress harmful genes while the other has marks that amplify them. This can explain why some individuals with no family history still develop heart disease, while others with strong genetic risk factors remain healthy.
The implications of this announcement are significant. Traditional risk assessments based on cholesterol, blood pressure, and family history often miss a large portion of people who will go on to have heart attacks or strokes. By incorporating epigenetic markers, Cardio Diagnostics aims to identify those hidden risks earlier and more accurately. This could lead to more personalized prevention strategies, such as tailored lifestyle interventions or targeted therapies that address the specific epigenetic changes driving disease. Moreover, because epigenetics can change over time in response to diet, exercise, stress, and other factors, repeat testing could monitor the effectiveness of interventions and guide adjustments.
For more information on the latest news and updates relating to CDIO, visit the company’s newsroom at https://ibn.fm/CDIO. Please see full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
Forward-looking statements in this article are subject to risks and uncertainties as described in the company’s SEC filings.
